相关实验视频

Updated: Mar 10, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

含有fotemustine的化疗表明毒性较低,有效性与高剂量甲醇基疗法相比相似:回顾性队列分析

Xudong Zhang¹, Wanyue Zhao¹, Wenhua Wang¹

¹Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Therapeutic advances in medical oncology

|March 9, 2026

概括

含有fotemustine的疗法在治疗初级中枢神经系统淋巴瘤 (PCNSL) 时,效果与高剂量甲状腺酸盐 (HD-MTX) 的效果相当. 这些fotemustine疗法在新诊断的PCNSL患者中提供了更安全的特征,并减少了不良事件.

科学领域:

在瘤学瘤学.
神经学神经学
药理学药理学是指药理学的学科.

背景情况:

初级中枢神经系统淋巴瘤 (PCNSL) 是一种罕见的,侵袭性的非霍奇金淋巴瘤.
基于高剂量甲状腺酸盐 (HD-MTX) 的化疗是目前的标准一线治疗.
含有fotemustine的疗法是一个潜在的替代方案,具有有前途的疗效和耐受性.

研究的目的:

为了比较含有fotemustine的疗法与含有HD-MTX的疗法的疗效,安全性和可行性.
评估新诊断的PCNSL患者的治疗结果.

主要方法:

在114名新诊断PCNSL患者的回顾性队列研究中.
两个队列:含有fotemustine (n=72) 和含有HD-MTX (n=42) 的队列.
主要终点:客观反应率 (ORR);次要终点:无进展生存率 (PFS),总生存率 (OS) 和不良事件 (AE).

主要成果:

在fotemustine和HD-MTX组之间可比的ORR (68%对67%,p=0.879).
在两个方案之间,PFS和OS结果相似.
基于fotemustine的治疗显示显著减少了包括白血病,血小板减少,消化毒性和粘膜炎 (p<0.05) 在内的副作用.

结论:

含有fotemustine的疗法在新诊断的PCNSL中具有与HD-MTX相似的疗效.
基于fotemustine的治疗提供了一个更安全的替代方案,具有减少AE概况.
这些发现支持fotemustine作为PCNSL治疗的可行选择.

关键词:

作为一线的治疗方法.摄影必须是必须的.免疫化学疗法免疫化学疗法甲基特雷克萨酸盐的使用方法主要的中枢神经系统淋巴瘤

更多相关视频

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

相关概念视频

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...